IMTM Immunopharm

IMTM’s proprietary new therapeutic concept PETIR™ Drug Design (Peptidase targeted immunoregulation) represents a powerful approach for inhibition of chronic inflammation. These unique PETIR™ technologies show a clear potency for a break-through in the treatment of a large number of inflammatory diseases that comprises but are not restricted to autoimmune diseases like multiple sclerosis and other neurodegenerative diseases or inflammatory bowel diseases, allergies like bronchial asthma, dermal diseases like acne or psoriasis up to transplant rejection and atherosclerosis.

IMTM’s first-in-class PETIR™ drugs have reached clinical development in multiple diseases.

IMTM will be happy providing you with more detailed information. For request please simply use the contact form.